Literature DB >> 1363056

Abnormal distribution of IL-6 receptor in aged MRL/lpr mice: elevated expression on B cells and absence on CD4+ cells.

I Kobayashi1, T Matsuda, T Saito, K Yasukawa, H Kikutani, T Hirano, T Taga, T Kishimoto.   

Abstract

A mAb against murine IL-6 receptor (IL-6R), KMH7, was obtained by immunization of hamster with recombinant soluble murine IL-6R. Flow cytometry analysis of IL-6R distribution on lymphocytes in BALB/c showed that IL-6R was expressed on peripheral lymph node (LN) T cells of either CD4+ or CD8+ phenotype, and Peyer's patch IgA+ B cells, but not on splenic B cells and thymocytes. A similar distribution was observed in 5 week old MRL/lpr and 16-week-old MRL/n mice. In contrast, in 16 week old MRL/lpr mice of both sexes, IL-6R was expressed on splenic IgM+ cells. Peripheral LN CD4+ T cells in 16 week old female MRL/lpr mice did not express IL-6R. Thymocytes in any population with a phenotype of CD4+ or CD8+, double negative, and double positive were not stained with KMH7 in both BALB/c and MRL/lpr mice. In both strains, IL-6R was induced in CD4+ or CD8+ thymocytes after 2 days of culture, suggesting that CD4+ thymocytes in MRL/lpr have a potential to express IL-6R. Our results suggest that overexpression of IL-6R on B cells and absence of IL-6R on peripheral CD4+ cells are concurrent with, or may contribute to, B cell hyperreactivity and T cell abnormality in this strain.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1363056     DOI: 10.1093/intimm/4.12.1407

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  8 in total

1.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Authors:  Gabor G Illei; Yuko Shirota; Cheryl H Yarboro; Jimmy Daruwalla; Edward Tackey; Kazuki Takada; Thomas Fleisher; James E Balow; Peter E Lipsky
Journal:  Arthritis Rheum       Date:  2010-02

2.  Dendritic cells from lupus-prone mice are defective in repressing immunoglobulin secretion.

Authors:  Mileka R Gilbert; Diane G Carnathan; Patricia C Cogswell; Li Lin; Albert S Baldwin; Barbara J Vilen
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

Review 3.  The role of cytokines in the immunopathogenesis of lupus.

Authors:  B S Handwerger; V Rus; L da Silva; C S Via
Journal:  Springer Semin Immunopathol       Date:  1994

Review 4.  Rationale for interleukin-6 blockade in systemic lupus erythematosus.

Authors:  E Tackey; P E Lipsky; G G Illei
Journal:  Lupus       Date:  2004       Impact factor: 2.911

5.  Regulation of interleukin-6 and interleukin-6R alpha (gp80) expression by murine immunoglobulin-secreting B-cell hybridomas.

Authors:  T Iwasaki; T Hamano; J Fujimoto; E Kakishita
Journal:  Immunology       Date:  1998-04       Impact factor: 7.397

6.  Regulation of cytokine expression by an autoreactive B cell clone derived from MRL/MP-lpr/lpr mice.

Authors:  T Iwasaki; T Hamano; J Fujimoto; A Ogata; E Kakishita
Journal:  Clin Exp Immunol       Date:  1998-10       Impact factor: 4.330

7.  Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus.

Authors:  H B Richards; M Satoh; M Shaw; C Libert; V Poli; W H Reeves
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307

8.  Interleukin 6 Accelerates Mortality by Promoting the Progression of the Systemic Lupus Erythematosus-Like Disease of BXSB.Yaa Mice.

Authors:  Shweta Jain; Giljun Park; Thomas J Sproule; Gregory J Christianson; Caroline M Leeth; Hongsheng Wang; Derry C Roopenian; Herbert C Morse
Journal:  PLoS One       Date:  2016-04-06       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.